HALLBERD Reviews

Halberd Corporation is known for its innovative work in the field of pharmaceuticals. One of their key products is the patented LDN+ Drug, a combination of low-dose Naltrexone and Cyclobenzaprine. This drug is a central part of a Cooperative Research and Development Agreement (CRADA) contract. The drug is currently undergoing a significant Safety Trial Protocol under a CRADA contract for Military Active Duty and Veterans. The six-week safety study subjects are current active-duty and retired military volunteers. The drug is believed to act as an antagonist against chemical and alcohol addiction and to relieve pain and anxiety linked to more severe mental health issues facing the military today. The company plans to obtain FDA clearance for the combined new pharmaceutical, pending the results of this limited pilot safety trial. The CEO of Halberd Corporation, William Hartman, has expressed that this is a huge step forward for the corporation. The company also offers 24/7 physiological and psychological patient tracking technologies via cloud-based systems developed by the team with new biomarker assessments. The company's website provides updates on the latest developments from Halberd. The company adheres fully to OTC Market reporting regulations and aims to augment the company's value for stockholders and generate interest from potential development partners. Halberd Corporation is a publicly traded entity on the OTC Market.